Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Early triple-negative breast cancer, drawn from the whole corpus: 171 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial has tested capecitabine or olaparib on top of adjuvant pembrolizumab for residual disease.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
About a third of patients do not reach a complete response and most relapses come from them.
Nothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Immune-related endocrine side effects are permanent in a few percent of women who would have been cured anyway.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Black women have twice the incidence and worse outcomes, and trial enrolment does not reflect this.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 25 changes by month →When this page itself was last checked or edited.
EFS HR 0.
iDFS HR 1.
Primary DFS endpoint not met (figures not indexed); exploratory: avelumab benefit only with baseline TILs 30% or more (stratum B 3-year DDFS 92.
pCR 58% (48 to 67); RCB 0 or 1 69%; 3-year EFS 86% (98% with pCR, 68% without).
Germline BRCA group: three-year survival 100 percent (39 patients, one relapse) with the gap schedule versus 88 percent (45 patients, nine relapses) with chemotherapy alone (University of Cambridge release on the Nature 2024 paper).